These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 25850892

  • 1. Interreader and inter-test agreement in assessing treatment response following transarterial embolization for hepatocellular carcinoma.
    Donati OF, Do RK, Hötker AM, Katz SS, Zheng J, Moskowitz CS, Beattie C, Brown KT.
    Eur Radiol; 2015 Sep; 25(9):2779-88. PubMed ID: 25850892
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.
    Gordic S, Corcuera-Solano I, Stueck A, Besa C, Argiriadi P, Guniganti P, King M, Kihira S, Babb J, Thung S, Taouli B.
    J Hepatol; 2017 Dec; 67(6):1213-1221. PubMed ID: 28823713
    [Abstract] [Full Text] [Related]

  • 3. Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria.
    Shim JH, Han S, Shin YM, Yu E, Park W, Kim KM, Lim YS, Lee HC.
    J Vasc Interv Radiol; 2013 Mar; 24(3):316-25. PubMed ID: 23312990
    [Abstract] [Full Text] [Related]

  • 4. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma.
    Riaz A, Miller FH, Kulik LM, Nikolaidis P, Yaghmai V, Lewandowski RJ, Mulcahy MF, Ryu RK, Sato KT, Gupta R, Wang E, Baker T, Abecassis M, Benson AB, Nemcek AA, Omary R, Salem R.
    JAMA; 2010 Mar 17; 303(11):1062-9. PubMed ID: 20233824
    [Abstract] [Full Text] [Related]

  • 5. Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?
    Zhao Y, Duran R, Bai W, Sahu S, Wang W, Kabus S, Lin M, Han G, Geschwind JF.
    Cardiovasc Intervent Radiol; 2018 Mar 17; 41(3):433-442. PubMed ID: 29086058
    [Abstract] [Full Text] [Related]

  • 6. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
    Shuster A, Huynh TJ, Rajan DK, Marquez MA, Grant DR, Huynh DC, Jaskolka JD.
    J Vasc Interv Radiol; 2013 Jun 17; 24(6):805-12. PubMed ID: 23562641
    [Abstract] [Full Text] [Related]

  • 7. Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation.
    Dioguardi Burgio M, Ronot M, Bruno O, Francoz C, Paradis V, Castera L, Durand F, Soubrane O, Vilgrain V.
    Liver Transpl; 2016 Nov 17; 22(11):1491-1500. PubMed ID: 27543821
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    Jung ES, Kim JH, Yoon EL, Lee HJ, Lee SJ, Suh SJ, Lee BJ, Seo YS, Yim HJ, Seo TS, Lee CH, Yeon JE, Park JJ, Kim JS, Bak YT, Byun KS.
    J Hepatol; 2013 Jun 17; 58(6):1181-7. PubMed ID: 23395691
    [Abstract] [Full Text] [Related]

  • 9. Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis.
    Vincenzi B, Di Maio M, Silletta M, D'Onofrio L, Spoto C, Piccirillo MC, Daniele G, Comito F, Maci E, Bronte G, Russo A, Santini D, Perrone F, Tonini G.
    PLoS One; 2015 Jun 17; 10(7):e0133488. PubMed ID: 26230853
    [Abstract] [Full Text] [Related]

  • 10. Reproducibility of mRECIST in Measurement and Response Assessment for Hepatocellular Carcinoma Treated by Transarterial Chemoembolization.
    Choi MH, Park GE, Oh SN, Park MY, Rha SE, Lee YJ, Jung SE, Choi JI.
    Acad Radiol; 2018 Nov 17; 25(11):1363-1373. PubMed ID: 29555570
    [Abstract] [Full Text] [Related]

  • 11. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602.
    Sato Y, Watanabe H, Sone M, Onaya H, Sakamoto N, Osuga K, Takahashi M, Arai Y, Japan Interventional Radiology in Oncology Study Group-JIVROSG.
    Ups J Med Sci; 2013 Mar 17; 118(1):16-22. PubMed ID: 23167460
    [Abstract] [Full Text] [Related]

  • 12. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization.
    Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, Meyer T.
    J Hepatol; 2011 Dec 17; 55(6):1309-16. PubMed ID: 21703196
    [Abstract] [Full Text] [Related]

  • 13. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models.
    Shim JH, Lee HC, Kim SO, Shin YM, Kim KM, Lim YS, Suh DJ.
    Radiology; 2012 Feb 17; 262(2):708-18. PubMed ID: 22187634
    [Abstract] [Full Text] [Related]

  • 14. EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma.
    Liu L, Wang W, Chen H, Zhao Y, Bai W, Yin Z, He C, Jia J, Yang M, Xia J, Fan D, Han G.
    Clin Cancer Res; 2014 Mar 15; 20(6):1623-31. PubMed ID: 24493832
    [Abstract] [Full Text] [Related]

  • 15. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation.
    Nicolini D, Agostini A, Montalti R, Mocchegiani F, Mincarelli C, Mandolesi A, Robertson NL, Candelari R, Giovagnoni A, Vivarelli M.
    World J Gastroenterol; 2017 May 28; 23(20):3690-3701. PubMed ID: 28611522
    [Abstract] [Full Text] [Related]

  • 16. Interobserver agreement of semi-automated and manual measurements of functional MRI metrics of treatment response in hepatocellular carcinoma.
    Bonekamp D, Bonekamp S, Halappa VG, Geschwind JF, Eng J, Corona-Villalobos CP, Pawlik TM, Kamel IR.
    Eur J Radiol; 2014 Mar 28; 83(3):487-96. PubMed ID: 24387824
    [Abstract] [Full Text] [Related]

  • 17. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
    Gavanier M, Ayav A, Sellal C, Orry X, Claudon M, Bronowicki JP, Laurent V.
    Eur J Radiol; 2016 Jan 28; 85(1):103-112. PubMed ID: 26724654
    [Abstract] [Full Text] [Related]

  • 18. Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants.
    Bargellini I, Bozzi E, Campani D, Carrai P, De Simone P, Pollina L, Cioni R, Filipponi F, Bartolozzi C.
    Eur J Radiol; 2013 May 28; 82(5):e212-8. PubMed ID: 23332890
    [Abstract] [Full Text] [Related]

  • 19. Inter-observer variability of response evaluation criteria for hepatocellular carcinoma treated with chemoembolization.
    Kim BK, Kim KA, Kim MJ, Park JY, Kim DY, Ahn SH, Han KH, Kim SU, Park MS.
    Dig Liver Dis; 2015 Aug 28; 47(8):682-8. PubMed ID: 25977216
    [Abstract] [Full Text] [Related]

  • 20. Inter-center agreement of mRECIST in transplanted patients for hepatocellular carcinoma.
    Vicentin I, Mosconi C, Garanzini E, Sposito C, Serenari M, Buscemi V, Verna M, Spreafico C, Golfieri R, Mazzaferro V, De Carlis L, Cescon M, Ercolani G, Vanzulli A, Cucchetti A.
    Eur Radiol; 2021 Dec 28; 31(12):8903-8912. PubMed ID: 34117911
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.